The distinction between decreased uric acid excretion and increased uric acid production is important for the clinical typing of hyperuricemia and gout and for guiding the use of medications. In previous clinical work, the distinction was mostly made by the 24-hour uric acid quantification method. After 5 days on a low purine diet, a 24-hour uric acid excretion of less than 600 mg (3.6 mmol) was defined as reduced uric acid excretion, and a 24-hour uric acid excretion of more than 800 mg (4.8 mmol) was defined as excessive uric acid production. It has also been suggested that uric acid excretion fraction should be used for typing. The fractional excretion of uric acid (FEUA) is calculated according to the following formula: FEUA = (blood creatinine X 24-hour urinary uric acid) / (blood uric acid X 24-hour urinary creatinine), expressed as a percentage. According to the results of uric acid excretion fraction, hyperuricemia and gout are classified into three types: reduced excretion type ( FEUA < 7%), mixed type ( 7% ≤ FEUA ≤ 12%) and increased production type ( FEUA > 12%). This index better reflects the excretion of uric acid by the kidneys. The former inhibits the reabsorption of uric acid in the renal tubules and increases the excretion of uric acid to lower the blood uric acid, so it is suitable for the type with reduced uric acid excretion, while the inhibitor of uric acid production mainly inhibits the activity of xanthine oxidase, thus reducing the biosynthesis of uric acid. Therefore, it is more effective for the type with increased uric acid production. Therefore, according to the clinical classification of 24-hour uric acid or FEUA, the type with reduced uric acid excretion should be treated with benzbromarone, while the type with increased uric acid production or mixed type should be treated with allopurinol or febuxostat, so that the correct choice of uric acid-lowering drugs can achieve the purpose of reducing blood uric acid.